ORLANDO — An all-oral combination of venetoclax plus ibrutinib in the frontline setting was well tolerated and associated with high rates of minimal residual disease in the blood and bone marrow of patients with chronic lymphocytic leukemia after 1 year of therapy, according to results of the phase 2 CAPTIVATE trial presented at the ASH Annual Meeting and Exposition.